Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older -

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Infection and infectious diseases | Later life | Vaccination
Summary
RCT (n=9004) showed quadrivalent, recombinant influenza (IF) vaccine as compared with standard-dose, egg-grown, quadrivalent, inactivated IF vaccine, improved protection against laboratory-confirmed IF-like illness in this group during A/H3N2-predominant 2014–2015 IF season in US
UKMi comment
This study was conducted during a period when antigenic mismatch between circulating and vaccine influenza strains resulted in the reduced effectiveness of many licensed vaccines in US.
Related links: